Tag: hydroxychloroquine

1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death. Evidence Rating Level: 2 (Good) There is ongoing research into evaluating potential treatment options for COVID-19. Despite conflicting evidence, hydroxychloroquine (with or without azithromycin) remains a popular option, while  preliminary results...

1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death. Evidence Rating Level: 2 (Good) There is ongoing research into evaluating potential treatment options for COVID-19. Despite conflicting evidence, hydroxychloroquine (with or without azithromycin) remains a popular option, while  preliminary results...

1. Prophylactic use of hydroxychloroquine within four days after exposure did not decrease cumulative incidence of coronavirus disease 2019 (Covid-19). 2. No arrhythmias or deaths occurred in the hydroxychloroquine or placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19). The...

1. Metformin was found to be safe and tolerable in survivors of pediatric brain tumors. 2. Metformin was associated with retention of memory and processing speed abilities, as well as a reduction of white matter loss. Evidence Rating Level: 1 (Excellent) It is believed that endogenous neural precursor cells (NPCs) can promote...

1. Prophylactic use of hydroxychloroquine within four days after exposure did not decrease cumulative incidence of coronavirus disease 2019 (Covid-19). 2. No arrhythmias or deaths occurred in the hydroxychloroquine or placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19). The...

1. Hydroxychloroquine use with or without azithromycin did not improve clinical outcomes at fifteen days when compared with standard of care in hospitalized patients with mild-to-moderate Covid-19. 2. A higher rate of side effects – including QT prolongation and elevated liver enzymes - was observed in patients taking hydroxychloroquine alone...

1. In this double-blind, randomized trial, hydroxychloroquine did not reduce symptom severity in an adult, outpatient population. 2. More side effects, mainly gastrointestinal symptoms, were experienced by the patients in the treatment group. Evidence Rating Level: 1 (Excellent) Study Rundown: There are currently no effective oral therapies for the outpatient treatment of...

1. In this double-blind, randomized trial, hydroxychloroquine did not reduce symptom severity in an adult, outpatient population. 2. More side effects, mainly gastrointestinal symptoms, were experienced by the patients in the treatment group. Evidence Rating Level: 1 (Excellent) Study Rundown: There are currently no effective oral therapies for the outpatient treatment of...

1. Hydroxychloroquine use as post-exposure prophylaxis within 4 days of a moderate or high-risk exposure did not prevent illness compatible with Covid-19 when compared to placebo. 2. Approximately 40% of individuals taking hydroxychloroquine reported side effects, all of which were noted to be mild and GI-related. There were no serious...

1. Use of hydroxychloroquine with or without azithromycin to treat COVID-19 was frequently associated with QTc prolongation, with results being more pronounced for patients taking both hydroxychloroquine and azithromycin. 2. Likelihood of QTc prolongation was greater with concomitant usage of loop diuretics. Evidence Rating: 2 (Good) Although studies have found varying degrees of...